Email
IZ Express #1,719: New COVID-19 and maternal RSV vaccine recommendations in MMWR, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,719: New COVID-19 and maternal RSV vaccine recommendations in MMWR, and more |
| Date | October 18, 2023 10:00 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,719: October 18, 2023
Top Stories
* "Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023" published in MMWR Early Release
* "Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
* CDC releases new Immunization Information Statement (a VIS-like document) for Respiratory Syncytial Virus (RSV) Preventive Antibody (nirsevimab)
* Immunize.org posts five new and updated translations of Vaccine Information Statements
* Immunize.org retires four of its resources summarizing recommendations and contraindications
* “Vaccination after COVID-19 Illness”: watch the 2-minute answer, part of the Ask the Experts Video Series on Facebook, LinkedIn, X (Twitter), YouTube, and Instagram
* Spotlight: Immunize.org resources focused on each vaccine-preventable disease, in photo, narrative, and Q&A formats
* Keep up with influenza this season: use CDC’s FluView and RESP-NET surveillance reports and Influenza Vaccination Dashboard, updated weekly
* Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements now features 1,335 organizations, including one new facility
* Vaccines in the news
Immunize.org Pages and Handouts
* Immunize.org updates its “Vaccines: COVID-19” main page to reflect recommended use of the 2023–2024 formula vaccines
Notable Publications
* "High Influenza Incidence and Disease Severity among Children and Adolescents Aged <18 Years―United States, 2022–23 Season" published in MMWR
Upcoming Events
* Virtual: Watch October 25–26 ACIP meeting. Topics include immunization schedules and seven vaccine-preventable diseases.
* Virtual: National Foundation for Infectious Diseases hosts "Clinical Vaccinology Course" on November 15–17; CME and CNE available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
"Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023" published in MMWR Early Release
CDC published Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023 ([link removed]) in the October 10 issue of MMWR Early Release. This publication summarizes decisions made by ACIP at its September 12 meeting ([link removed]) and information updated online at CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States ([link removed]). A portion of the article's summary appears below.
Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines were designed to protect against are no longer circulating widely. In September and October 2023, the Food and Drug Administration approved and authorized updated 2023–2024 Formula monovalent XBB.1.5 component–containing COVID-19 vaccines, formulated to target current variants more closely, specifically Omicron variant XBB.1.5, for persons aged ≥6 months. . . .
On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. . . .
The updated COVID-19 vaccines are meant to broaden vaccine-induced immunity and provide protection against the currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19–associated illness and death.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to the MMWR family of publications
------------------------------------------------------------
"Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
CDC published Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 ([link removed]) on October 13 in MMWR ([link removed]). This article reflects decisions made by ACIP at its meeting on September 22 ([link removed]). A portion of the article's summary appears below.
Nirsevimab is recommended in infants to prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI). In August 2023, the Food and Drug Administration approved Pfizer RSV vaccine for pregnant persons at 32–36 weeks’ gestation to prevent RSV-associated LRTI in infants aged <6 months. . . .
On September 22, 2023, CDC’s Advisory Committee on Immunization Practices recommended RSV vaccine for pregnant persons at 32–36 weeks’ gestation using seasonal administration (meaning September–January in most of the United States) to prevent RSV-associated LRTI in infants aged <6 months. . . .
CDC recommends protecting all infants against RSV-associated LRTI through use of either the maternal RSV vaccine or infant receipt of nirsevimab.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to the MMWR family of publications
------------------------------------------------------------
CDC releases new Immunization Information Statement (a VIS-like document) for Respiratory Syncytial Virus (RSV) Preventive Antibody (nirsevimab)
On September 25, CDC released a new Immunization Information Statement (IIS) (similar in format to a Vaccine Information Statement [VIS]), for Respiratory Syncytial Virus (RSV) Preventive Antibody ([link removed]) (nirsevimab). This IIS document contains important information about the new preventive antibody product for families. Access the IIS in PDF ([link removed]) or RTF file ([link removed]) (for use in electronic systems).
[link removed]
At this time, the RSV preventive antibody is not part of the Vaccine Injury Compensation Program (VICP), therefore use of the IIS is not required by federal law in the way that VIS use is required for vaccines covered by the VICP. However, as a condition of participating in the Vaccines for Children (VFC) program, providers must give the IIS to parents in the same way that a VIS is provided.
Related Links
* CDC: Respiratory Syncytial Virus (RSV) Preventive Antibody: Immunization Information Statement (IIS) ([link removed]) web page
* CDC: Respiratory Syncytial Virus (RSV) Immunizations ([link removed]) web page
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
------------------------------------------------------------
Immunize.org posts five new and updated translations of Vaccine Information Statements
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
On July 24, CDC released an updated interim VIS for Pediatric Multi-vaccines (Your Child's First Vaccines) ([link removed]) and on May 12, CDC released interim VISs for Hepatitis B Vaccine ([link removed]) and Pneumococcal Conjugate (PCV) Vaccine ([link removed]). Immunize.org posted two translations for each, generously donated by St. Peter's Health Partners of Albany, NY.
Hepatitis B Vaccine (view in English ([link removed])):
* Burmese ([link removed])
* Karen ([link removed])
Pneumococcal Conjugate Vaccine (view in English ([link removed])):
* Burmese ([link removed])
* Karen ([link removed])
Your Child’s First Vaccines (view in English ([link removed])):
* New! Karen ([link removed])
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Immunize.org retires four of its resources summarizing recommendations and contraindications
After many years as valuable and popular references, Immunize.org retired four of its more than 230 resources for healthcare professionals. The CDC child/adolescent and adult recommended immunization schedules ([link removed]) now incorporate detailed clinical notes and list the contraindications and precautions for vaccines on the schedule. In addition, CDC schedules are now updated online more frequently, as new ACIP recommendations and changes to the schedules are made. As a result, the following Immunize.org documents were retired as redundant and users are referred to the CDC schedules ([link removed]) for the information:
* Summary of Recommendations for Child/Teen Immunization (Age birth through 18 years)
* Summary of Recommendations for Adult Immunization (Age 19 years and older)
* Guide to Contraindications and Precautions to Commonly Used Vaccines in Adults
* Guide to Contraindications and Precautions to Commonly Used Vaccines for All Ages
Immunize.org remains focused on connecting healthcare professionals with the resources you need to achieve excellence in your immunization practice.
Related Link
* CDC: Recommended Immunization Schedules ([link removed]) main page
------------------------------------------------------------
“Vaccination after COVID-19 Illness”: watch the 2-minute answer, part of the Ask the Experts Video Series on Facebook, LinkedIn, X (Twitter), YouTube, and Instagram
Immunize.org's social media channels make it easy for you to learn a little more every day. This week, our featured episode from the Ask the Experts Video Series is Vaccination after COVID-19 Illness ([link removed]). This is available on our YouTube channel ([link removed]), along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at Immunize.org ([link removed])
* X (Twitter) at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
------------------------------------------------------------
Spotlight: Immunize.org resources focused on each vaccine-preventable disease, in photo, narrative, and Q&A formats
Immunize.org offers a host of materials that focus on specific vaccine-preventable diseases. Here are some highlights.
Vaccines ([link removed]) main page leads viewers to 24 pages, one for each vaccine-preventable disease. These pages provide curated materials from public health authorities and Immunize.org on each disease and vaccine.
Ask the Experts ([link removed]) main page gives you access to more than 1,200 questions answered by Immunize.org experts. Topics include specific diseases and their vaccines as well as vaccine delivery guidance (e.g., administration, billing, documenting).
Advisory Committee on Immunization Practices (ACIP) ([link removed]) main page links to all current ACIP vaccine recommendations as well as most dating back to 1991. You can sort the ACIP recommendations by diseases or publication date.
Unprotected People Stories ([link removed]) main page features more than 100 real-life accounts of people who suffered or died from vaccine-preventable diseases. There are compelling personal testimonies, remembrances, case reports, and newspaper articles.
Image Library ([link removed]) main page offers hundreds of photos of people affected by vaccine-preventable diseases; micrographs of viruses, bacteria, and pathology specimens; and pictures of people being vaccinated. Please follow noted copyright requirements.
------------------------------------------------------------
Keep up with influenza this season: use CDC’s FluView and RESP-NET surveillance reports and Influenza Vaccination Dashboard, updated weekly
Influenza and RSV seasons have begun. CDC expects respiratory virus activity, including influenza, which is currently low, to increase. CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), provides a valuable snapshot of influenza activity state-by-state.
Influenza Surveillance
For week 40, ending October 7, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]) reports that, nationwide, 2.2% of patient visits reported through the Outpatient Influenza-Like Illness Surveillance Network (ILINet) were due to respiratory illness that included fever plus a cough or sore throat (i.e., influenza-like illness [ILI]). This is below the national baseline of 2.5%. One influenza-associated pediatric death that occurred during the 2022–2023 season was reported this week.
On October 12, 2023, CDC posted a web spotlight ([link removed]) reporting two fatal human infections with highly pathogenic avian influenza (HPAI)A H5N1 (bird flu) virus in Cambodia.
RESP-NET
Visit the CDC Respiratory Virus Hospitalization Surveillance Network (RESP-NET) ([link removed]) for weekly reports of hospitalizations across the United States due to the three vaccine-preventable seasonal respiratory viruses: COVID-19, influenza, and RSV.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) data show that 116 million doses of influenza vaccine have been shipped within the United States through September 30, 2023.
CDC recommends everyone age 6 months and older get annual influenza vaccination. Influenza and other vaccines (e.g., COVID-19 vaccine, RSV vaccine) may be given at the same visit, if needed. Locate influenza and COVID-19 vaccines in your area by entering your zip code in the VaccineFinder on Vaccines.gov or Vacunas.gov. To be listed as a provider by VaccineFinder, see the information on this website ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: RESP-NET ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
------------------------------------------------------------
Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements now features 1,335 organizations, including one new facility
Immunize.org's Influenza Vaccination Honor Roll ([link removed]) recognizes facilities that take a stand for patient safety by implementing policies requiring healthcare personnel influenza vaccination. There are now 1,335 organizations enrolled. Immunize.org recently welcomed an additional healthcare organization.
* STRIDE Community Health Center, Denver, CO
[link removed]
Eligibility:
* Eligible organizations: hospitals, long-term care facilities, medical practices, pharmacies, professional organizations, health departments, and other government entities
* Requirements:
+ Your policy must require influenza vaccination for all staff
+ The application ([link removed]) must describe measures to prevent transmission of influenza from unvaccinated personnel to patients (e.g., masking for the entire work shift)
Related Links
* Immunize.org: list of Influenza Vaccination Honorees, all healthcare settings ([link removed]), by state
* Immunize.org: Long-Term Care/Assisted Living Influenza Vaccination Honorees ([link removed]) by state
* Immunize.org: Influenza Vaccination Honor Roll program ([link removed]), including:
+ Position statements ([link removed]) from professional societies and leading healthcare organizations in support of requiring influenza vaccination
+ Application form for Influenza Vaccination Honor Roll ([link removed])
* Immunize.org: Honor Roll for Patient Safety ([link removed]) web page
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* HHS: Project NextGen Selects Initial Vaccine Candidates and Awards over $500 Million to Advance Development of Vaccines and Therapeutics ([link removed]) (10/13/23)
* Scientific American: The Flu Vaccine Works—In a Way Most People Don’t Appreciate ([link removed]) (10/9/23)
* CNN: Older Adults Still Make Up Most COVID-19 Hospitalizations, CDC Report Says, but Concern Grows over Lack of Vaccination ([link removed]) (10/9/23)
* Contemporary Pediatrics: What’s New in Pediatric Vaccines ([link removed]) (10/9/23)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Immunize.org updates its “Vaccines: COVID-19” main page to reflect recommended use of the 2023–2024 formula vaccines
Immunize.org updated its Vaccines: COVID-19 ([link removed]) main page. Outdated information about bivalent mRNA vaccines was removed and users will now find current content on the 2023–2024 formula products. The web page continues to direct visitors seeking quick links to all print-ready federal fact sheets and COVID-19 vaccination resources to Immunize.org’s Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]), which is updated at least monthly. The web page also continues to link to other important government and partner websites.
Bookmark Immunize.org's Vaccines: COVID-19 ([link removed]) main page to connect with a comprehensive list of resources from CDC and FDA including fact sheets, clinical considerations, vaccine administration tools, and storage and handling guidance.
Related Links
* Immunize.org: Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (PDF)
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page
* CDC: Interim Clinical Considerations ([link removed]) main page summarizing use of COVID-19 vaccines in the United States
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
"High Influenza Incidence and Disease Severity among Children and Adolescents Aged <18 Years―United States, 2022–23 Season" published in MMWR
CDC published High Influenza Incidence and Disease Severity among Children and Adolescents Aged <18 Years―United States, 2022–23 Season ([link removed]) on October 13 in MMWR. A portion of the article's summary appears below.
The 2022–23 influenza season began early, coinciding with circulation of other respiratory viruses. High hospitalization rates among children and adolescents were observed. . . .
Among children and adolescents aged <18 years, 2022–23 was a high severity influenza season compared with thresholds based on previous seasons’ data; influenza-associated medical visits and hospitalizations met or exceeded incidence in previous seasons. . . .
CDC recommends that all persons aged ≥6 months without contraindications should receive the annual seasonal influenza vaccine, ideally by the end of October.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to the MMWR family of publications
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Watch October 25–26 ACIP meeting. Topics include immunization schedules and seven vaccine-preventable diseases.
CDC will convene a 2-day meeting of the Advisory Committee on Immunization Practices ([link removed]) (ACIP), October 25–26, starting at 8:00 a.m. (ET). ACIP will discuss child and adolescent immunization schedules, adult immunization schedule, influenza, chikungunya, COVID–19, meningococcal, mpox, and pneumococcal vaccines, as well as RSV vaccines for older adults. Votes on immunization schedules, meningococcal vaccines, and mpox vaccine are scheduled.
No registration is required to watch webcasts of live ACIP meetings or listen via telephone. Opportunities for public comment are described on the website.
View the agenda ([link removed]).
Related Links
* CDC: ACIP main page ([link removed]) for access to webcast, agendas
* CDC: ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
------------------------------------------------------------
Virtual: National Foundation for Infectious Diseases hosts "Clinical Vaccinology Course" on November 15–17; CME and CNE available
The National Foundation of Infectious Diseases ([link removed]) (NFID) Clinical Vaccinology Course ([link removed]) will be held online November 15–17. This 3-day online course focuses on new developments and issues related to use of vaccines. Expert faculty provide the latest information on vaccines, including updated recommendations for vaccinations across the lifespan, and innovative and practical strategies for ensuring timely and appropriate vaccination.
Continuing medical education (CME) and continuing nursing education (CNE) ([link removed]) credit will be offered.
Register for the online course ([link removed]) ($700 fee).
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,719: October 18, 2023
Top Stories
* "Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023" published in MMWR Early Release
* "Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
* CDC releases new Immunization Information Statement (a VIS-like document) for Respiratory Syncytial Virus (RSV) Preventive Antibody (nirsevimab)
* Immunize.org posts five new and updated translations of Vaccine Information Statements
* Immunize.org retires four of its resources summarizing recommendations and contraindications
* “Vaccination after COVID-19 Illness”: watch the 2-minute answer, part of the Ask the Experts Video Series on Facebook, LinkedIn, X (Twitter), YouTube, and Instagram
* Spotlight: Immunize.org resources focused on each vaccine-preventable disease, in photo, narrative, and Q&A formats
* Keep up with influenza this season: use CDC’s FluView and RESP-NET surveillance reports and Influenza Vaccination Dashboard, updated weekly
* Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements now features 1,335 organizations, including one new facility
* Vaccines in the news
Immunize.org Pages and Handouts
* Immunize.org updates its “Vaccines: COVID-19” main page to reflect recommended use of the 2023–2024 formula vaccines
Notable Publications
* "High Influenza Incidence and Disease Severity among Children and Adolescents Aged <18 Years―United States, 2022–23 Season" published in MMWR
Upcoming Events
* Virtual: Watch October 25–26 ACIP meeting. Topics include immunization schedules and seven vaccine-preventable diseases.
* Virtual: National Foundation for Infectious Diseases hosts "Clinical Vaccinology Course" on November 15–17; CME and CNE available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
"Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023" published in MMWR Early Release
CDC published Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023 ([link removed]) in the October 10 issue of MMWR Early Release. This publication summarizes decisions made by ACIP at its September 12 meeting ([link removed]) and information updated online at CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States ([link removed]). A portion of the article's summary appears below.
Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines were designed to protect against are no longer circulating widely. In September and October 2023, the Food and Drug Administration approved and authorized updated 2023–2024 Formula monovalent XBB.1.5 component–containing COVID-19 vaccines, formulated to target current variants more closely, specifically Omicron variant XBB.1.5, for persons aged ≥6 months. . . .
On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. . . .
The updated COVID-19 vaccines are meant to broaden vaccine-induced immunity and provide protection against the currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19–associated illness and death.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to the MMWR family of publications
------------------------------------------------------------
"Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
CDC published Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 ([link removed]) on October 13 in MMWR ([link removed]). This article reflects decisions made by ACIP at its meeting on September 22 ([link removed]). A portion of the article's summary appears below.
Nirsevimab is recommended in infants to prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI). In August 2023, the Food and Drug Administration approved Pfizer RSV vaccine for pregnant persons at 32–36 weeks’ gestation to prevent RSV-associated LRTI in infants aged <6 months. . . .
On September 22, 2023, CDC’s Advisory Committee on Immunization Practices recommended RSV vaccine for pregnant persons at 32–36 weeks’ gestation using seasonal administration (meaning September–January in most of the United States) to prevent RSV-associated LRTI in infants aged <6 months. . . .
CDC recommends protecting all infants against RSV-associated LRTI through use of either the maternal RSV vaccine or infant receipt of nirsevimab.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to the MMWR family of publications
------------------------------------------------------------
CDC releases new Immunization Information Statement (a VIS-like document) for Respiratory Syncytial Virus (RSV) Preventive Antibody (nirsevimab)
On September 25, CDC released a new Immunization Information Statement (IIS) (similar in format to a Vaccine Information Statement [VIS]), for Respiratory Syncytial Virus (RSV) Preventive Antibody ([link removed]) (nirsevimab). This IIS document contains important information about the new preventive antibody product for families. Access the IIS in PDF ([link removed]) or RTF file ([link removed]) (for use in electronic systems).
[link removed]
At this time, the RSV preventive antibody is not part of the Vaccine Injury Compensation Program (VICP), therefore use of the IIS is not required by federal law in the way that VIS use is required for vaccines covered by the VICP. However, as a condition of participating in the Vaccines for Children (VFC) program, providers must give the IIS to parents in the same way that a VIS is provided.
Related Links
* CDC: Respiratory Syncytial Virus (RSV) Preventive Antibody: Immunization Information Statement (IIS) ([link removed]) web page
* CDC: Respiratory Syncytial Virus (RSV) Immunizations ([link removed]) web page
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
------------------------------------------------------------
Immunize.org posts five new and updated translations of Vaccine Information Statements
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
On July 24, CDC released an updated interim VIS for Pediatric Multi-vaccines (Your Child's First Vaccines) ([link removed]) and on May 12, CDC released interim VISs for Hepatitis B Vaccine ([link removed]) and Pneumococcal Conjugate (PCV) Vaccine ([link removed]). Immunize.org posted two translations for each, generously donated by St. Peter's Health Partners of Albany, NY.
Hepatitis B Vaccine (view in English ([link removed])):
* Burmese ([link removed])
* Karen ([link removed])
Pneumococcal Conjugate Vaccine (view in English ([link removed])):
* Burmese ([link removed])
* Karen ([link removed])
Your Child’s First Vaccines (view in English ([link removed])):
* New! Karen ([link removed])
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Immunize.org retires four of its resources summarizing recommendations and contraindications
After many years as valuable and popular references, Immunize.org retired four of its more than 230 resources for healthcare professionals. The CDC child/adolescent and adult recommended immunization schedules ([link removed]) now incorporate detailed clinical notes and list the contraindications and precautions for vaccines on the schedule. In addition, CDC schedules are now updated online more frequently, as new ACIP recommendations and changes to the schedules are made. As a result, the following Immunize.org documents were retired as redundant and users are referred to the CDC schedules ([link removed]) for the information:
* Summary of Recommendations for Child/Teen Immunization (Age birth through 18 years)
* Summary of Recommendations for Adult Immunization (Age 19 years and older)
* Guide to Contraindications and Precautions to Commonly Used Vaccines in Adults
* Guide to Contraindications and Precautions to Commonly Used Vaccines for All Ages
Immunize.org remains focused on connecting healthcare professionals with the resources you need to achieve excellence in your immunization practice.
Related Link
* CDC: Recommended Immunization Schedules ([link removed]) main page
------------------------------------------------------------
“Vaccination after COVID-19 Illness”: watch the 2-minute answer, part of the Ask the Experts Video Series on Facebook, LinkedIn, X (Twitter), YouTube, and Instagram
Immunize.org's social media channels make it easy for you to learn a little more every day. This week, our featured episode from the Ask the Experts Video Series is Vaccination after COVID-19 Illness ([link removed]). This is available on our YouTube channel ([link removed]), along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at Immunize.org ([link removed])
* X (Twitter) at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
------------------------------------------------------------
Spotlight: Immunize.org resources focused on each vaccine-preventable disease, in photo, narrative, and Q&A formats
Immunize.org offers a host of materials that focus on specific vaccine-preventable diseases. Here are some highlights.
Vaccines ([link removed]) main page leads viewers to 24 pages, one for each vaccine-preventable disease. These pages provide curated materials from public health authorities and Immunize.org on each disease and vaccine.
Ask the Experts ([link removed]) main page gives you access to more than 1,200 questions answered by Immunize.org experts. Topics include specific diseases and their vaccines as well as vaccine delivery guidance (e.g., administration, billing, documenting).
Advisory Committee on Immunization Practices (ACIP) ([link removed]) main page links to all current ACIP vaccine recommendations as well as most dating back to 1991. You can sort the ACIP recommendations by diseases or publication date.
Unprotected People Stories ([link removed]) main page features more than 100 real-life accounts of people who suffered or died from vaccine-preventable diseases. There are compelling personal testimonies, remembrances, case reports, and newspaper articles.
Image Library ([link removed]) main page offers hundreds of photos of people affected by vaccine-preventable diseases; micrographs of viruses, bacteria, and pathology specimens; and pictures of people being vaccinated. Please follow noted copyright requirements.
------------------------------------------------------------
Keep up with influenza this season: use CDC’s FluView and RESP-NET surveillance reports and Influenza Vaccination Dashboard, updated weekly
Influenza and RSV seasons have begun. CDC expects respiratory virus activity, including influenza, which is currently low, to increase. CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), provides a valuable snapshot of influenza activity state-by-state.
Influenza Surveillance
For week 40, ending October 7, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]) reports that, nationwide, 2.2% of patient visits reported through the Outpatient Influenza-Like Illness Surveillance Network (ILINet) were due to respiratory illness that included fever plus a cough or sore throat (i.e., influenza-like illness [ILI]). This is below the national baseline of 2.5%. One influenza-associated pediatric death that occurred during the 2022–2023 season was reported this week.
On October 12, 2023, CDC posted a web spotlight ([link removed]) reporting two fatal human infections with highly pathogenic avian influenza (HPAI)A H5N1 (bird flu) virus in Cambodia.
RESP-NET
Visit the CDC Respiratory Virus Hospitalization Surveillance Network (RESP-NET) ([link removed]) for weekly reports of hospitalizations across the United States due to the three vaccine-preventable seasonal respiratory viruses: COVID-19, influenza, and RSV.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) data show that 116 million doses of influenza vaccine have been shipped within the United States through September 30, 2023.
CDC recommends everyone age 6 months and older get annual influenza vaccination. Influenza and other vaccines (e.g., COVID-19 vaccine, RSV vaccine) may be given at the same visit, if needed. Locate influenza and COVID-19 vaccines in your area by entering your zip code in the VaccineFinder on Vaccines.gov or Vacunas.gov. To be listed as a provider by VaccineFinder, see the information on this website ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: RESP-NET ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
------------------------------------------------------------
Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements now features 1,335 organizations, including one new facility
Immunize.org's Influenza Vaccination Honor Roll ([link removed]) recognizes facilities that take a stand for patient safety by implementing policies requiring healthcare personnel influenza vaccination. There are now 1,335 organizations enrolled. Immunize.org recently welcomed an additional healthcare organization.
* STRIDE Community Health Center, Denver, CO
[link removed]
Eligibility:
* Eligible organizations: hospitals, long-term care facilities, medical practices, pharmacies, professional organizations, health departments, and other government entities
* Requirements:
+ Your policy must require influenza vaccination for all staff
+ The application ([link removed]) must describe measures to prevent transmission of influenza from unvaccinated personnel to patients (e.g., masking for the entire work shift)
Related Links
* Immunize.org: list of Influenza Vaccination Honorees, all healthcare settings ([link removed]), by state
* Immunize.org: Long-Term Care/Assisted Living Influenza Vaccination Honorees ([link removed]) by state
* Immunize.org: Influenza Vaccination Honor Roll program ([link removed]), including:
+ Position statements ([link removed]) from professional societies and leading healthcare organizations in support of requiring influenza vaccination
+ Application form for Influenza Vaccination Honor Roll ([link removed])
* Immunize.org: Honor Roll for Patient Safety ([link removed]) web page
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* HHS: Project NextGen Selects Initial Vaccine Candidates and Awards over $500 Million to Advance Development of Vaccines and Therapeutics ([link removed]) (10/13/23)
* Scientific American: The Flu Vaccine Works—In a Way Most People Don’t Appreciate ([link removed]) (10/9/23)
* CNN: Older Adults Still Make Up Most COVID-19 Hospitalizations, CDC Report Says, but Concern Grows over Lack of Vaccination ([link removed]) (10/9/23)
* Contemporary Pediatrics: What’s New in Pediatric Vaccines ([link removed]) (10/9/23)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Immunize.org updates its “Vaccines: COVID-19” main page to reflect recommended use of the 2023–2024 formula vaccines
Immunize.org updated its Vaccines: COVID-19 ([link removed]) main page. Outdated information about bivalent mRNA vaccines was removed and users will now find current content on the 2023–2024 formula products. The web page continues to direct visitors seeking quick links to all print-ready federal fact sheets and COVID-19 vaccination resources to Immunize.org’s Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]), which is updated at least monthly. The web page also continues to link to other important government and partner websites.
Bookmark Immunize.org's Vaccines: COVID-19 ([link removed]) main page to connect with a comprehensive list of resources from CDC and FDA including fact sheets, clinical considerations, vaccine administration tools, and storage and handling guidance.
Related Links
* Immunize.org: Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (PDF)
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page
* CDC: Interim Clinical Considerations ([link removed]) main page summarizing use of COVID-19 vaccines in the United States
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
"High Influenza Incidence and Disease Severity among Children and Adolescents Aged <18 Years―United States, 2022–23 Season" published in MMWR
CDC published High Influenza Incidence and Disease Severity among Children and Adolescents Aged <18 Years―United States, 2022–23 Season ([link removed]) on October 13 in MMWR. A portion of the article's summary appears below.
The 2022–23 influenza season began early, coinciding with circulation of other respiratory viruses. High hospitalization rates among children and adolescents were observed. . . .
Among children and adolescents aged <18 years, 2022–23 was a high severity influenza season compared with thresholds based on previous seasons’ data; influenza-associated medical visits and hospitalizations met or exceeded incidence in previous seasons. . . .
CDC recommends that all persons aged ≥6 months without contraindications should receive the annual seasonal influenza vaccine, ideally by the end of October.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to the MMWR family of publications
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Watch October 25–26 ACIP meeting. Topics include immunization schedules and seven vaccine-preventable diseases.
CDC will convene a 2-day meeting of the Advisory Committee on Immunization Practices ([link removed]) (ACIP), October 25–26, starting at 8:00 a.m. (ET). ACIP will discuss child and adolescent immunization schedules, adult immunization schedule, influenza, chikungunya, COVID–19, meningococcal, mpox, and pneumococcal vaccines, as well as RSV vaccines for older adults. Votes on immunization schedules, meningococcal vaccines, and mpox vaccine are scheduled.
No registration is required to watch webcasts of live ACIP meetings or listen via telephone. Opportunities for public comment are described on the website.
View the agenda ([link removed]).
Related Links
* CDC: ACIP main page ([link removed]) for access to webcast, agendas
* CDC: ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
------------------------------------------------------------
Virtual: National Foundation for Infectious Diseases hosts "Clinical Vaccinology Course" on November 15–17; CME and CNE available
The National Foundation of Infectious Diseases ([link removed]) (NFID) Clinical Vaccinology Course ([link removed]) will be held online November 15–17. This 3-day online course focuses on new developments and issues related to use of vaccines. Expert faculty provide the latest information on vaccines, including updated recommendations for vaccinations across the lifespan, and innovative and practical strategies for ensuring timely and appropriate vaccination.
Continuing medical education (CME) and continuing nursing education (CNE) ([link removed]) credit will be offered.
Register for the online course ([link removed]) ($700 fee).
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp